



Scientists and Health Care Workers
Committed to HIV/AIDS

3rd International AIDS Society Conference on **HIV** Pathogenesis and Treatment

Rio de Janeiro - July 24 - 27, 2005

NON-INFECTIOUS X4 BUT NOT R5 HIV-1 VIRIONS INHIBIT HUMORAL IMMUNE RESPONSES IN HUMAN LYMPHOID TISSUE *EX VIVO*

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. MoOa0301

Grivel J.-C.¹, Fitzgerald W.S.², Sylwester A.¹, Lifson J.³, Margolis L.B.¹

¹National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1855, United States of America, ²NASA-NIH Center for Three-Dimensional Tissue Culture, Bethesda, MD 20892-1855, United States of America, ³AIDS Vaccine Program, SAIC Frederick, Inc., National Cancer Institute-Frederick, Frederick, MD 21702-1201, United States of America

INTRODUCTION: *Ex vivo* HIV-1 infection of human lymphoid tissue recapitulates some aspects of *in vivo* infection, including a severe depletion of CD4+ T cells and suppression of humoral immune responses to recall antigens or to polyclonal stimuli. To isolate the mechanisms of suppression of immune responses from T cell depletion, we used inactivated virions that do not deplete CD4+ T cells in human lymphoid tissues *ex vivo*.

METHODS: Humoral immune response of the tissue was evaluated by antigen-specific and total immunoglobulin productions after *ex vivo* challenge with Tetanus toxoid and pokeweed mitogen. Immunoglobulin production of these tissues was compared with that following exposure to AT-2 inactivated HIV-1.

RESULTS: AT-2 inactivated X4, but not R5 HIV-1 virions, even with only a brief exposure, inhibited antibody responses in human lymphoid tissue *ex vivo*. The efficiency of this inhibition was comparable to that mediated by infectious virus. The inhibition is dependent on the maintenance of native X4 virion structure since neither baculovirus-expressed gp120, nor heat-denatured AT-2-inactivated X4 virus inhibited immune responses of *ex vivo* human lymphoid tissue. Moreover, the virus itself is only required to trigger suppression of B cell responses; the suppressive activity is maintained without the continuous presence of virions and can be transferred by conditioned medium.

CONCLUSIONS: Thus, neither productive viral infection, nor CD4+ T cell depletion are necessary to mediate HIV-induced inhibition of antibody production in human

lymphoid tissue in *ex vivo*. This phenomenon is mediated by soluble immunosuppressive factor(s) (ISF) secreted by lymphoid tissue exposed to viral particles.

050724

Basic | MoOa0301 | Jean-charles Grivel

16.1 80 16.1 HIV-induced immune dysfunction and activation

Copyright © 2005 - [International AIDS Society](#) (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted grants from [Boehringer Ingelheim](#), [Bridgestone/Firestone Charitable Trust](#), [Bristol-Myers Squibb Company](#), [Elton John AIDS Foundation](#), the [National Library of Medicine](#), and [donations](#) from users like you. **Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.**

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. **Always discuss treatment options with a doctor who specializes in treating HIV.**

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.